Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone415-231-5660
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.51 million
Profitability
Miscellaneous
Employees91
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Alector (NASDAQ:ALEC) Frequently Asked Questions
What is Alector's stock symbol?
Alector trades on the NASDAQ under the ticker symbol "ALEC."
How were Alector's earnings last quarter?
Alector Inc (NASDAQ:ALEC) announced its earnings results on Monday, August, 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.03. The business earned $6.92 million during the quarter. View Alector's Earnings History.
When is Alector's next earnings date?
What price target have analysts set for ALEC?
6 analysts have issued 1-year target prices for Alector's stock. Their predictions range from $26.00 to $27.00. On average, they expect Alector's share price to reach $26.67 in the next year. This suggests a possible upside of 85.4% from the stock's current price. View Analyst Price Targets for Alector.
What is the consensus analysts' recommendation for Alector?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alector.
Has Alector been receiving favorable news coverage?
Press coverage about ALEC stock has been trending somewhat negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alector earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Alector.
Are investors shorting Alector?
Alector saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,530,000 shares, an increase of 34.5% from the August 30th total of 4,110,000 shares. Based on an average daily volume of 378,900 shares, the short-interest ratio is currently 14.6 days. Currently, 13.8% of the company's shares are sold short. View Alector's Current Options Chain.
Who are some of Alector's key competitors?
Some companies that are related to Alector include Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX) and Sangamo Therapeutics (SGMO).
What other stocks do shareholders of Alector own?
Who are Alector's key executives?
Alector's management team includes the folowing people:
- Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
- Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
- Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
- Dr. Robert S. King, Chief Devel. Officer (Age 56)
- Dr. Asa Abeliovich M.D., Ph.D., Co-Founder
When did Alector IPO?
(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.
How do I buy shares of Alector?
Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Alector's stock price today?
One share of ALEC stock can currently be purchased for approximately $14.39.
How big of a company is Alector?
Alector has a market capitalization of $990.12 million and generates $27.51 million in revenue each year. The company earns $-52,250,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Alector employs 91 workers across the globe.View Additional Information About Alector.
What is Alector's official website?
How can I contact Alector?
Alector's mailing address is 151 OYSTER POINT BLVD. SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]
MarketBeat Community Rating for Alector (NASDAQ ALEC)
MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote "Outperform" if you believe ALEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
